AIM: To assess whether the effectiveness of a combination of transarterial chemoembolization (TACE) and percutaneous ethanol injection (PEI) in the treatment of unresectable hepatocellular carcinoma (HCC) is superior to TACE alone a randomized controlled trial was performed. METHODS: The effect of combination therapy on long-term survival rates and duration of hospitalization was evaluated in 52 previously untreated HCCs, randomly allocated to TACE-PEI (27 pts) or TACE alone (25 pts). RESULTS: The cumulative survival rate of the TACE group was 75.8% at 6 mo, 62.9% at 12 mo, and 18.0% at 24 mo and of the TACE-PEI group 76.9%, 61.5%, and 38.7%, respectively. Comparison of overall survival in both groups showed no statistically significant difference. Regarding the patients with HCCs Okuda stageI (n = 26), the median survival of the TACE-PEI group was significantly longer (>24 mo, median not yet reached in the study period) compared to the TACE group (18.4 mo [range 11.6-21.7 mo]; P = 0.04). TACE-PEI reduced the relative risk for mortality to 0.4 (95%CI 0.15-0.96) compared to patients who received TACE alone. Median survival in patients with HCCs Okuda stage II or III was 5.0 mo in the TACE group (1.7 mo-not defined) compared to 10.4 mo in the TACE-PEI group. CONCLUSION: The combination TACE-PEI improved survival time compared to TACE alone. Our study revealed a statistically significant improved survival in HCCs Okuda stage I. Side effects were minor and the combination therapy did not prolong duration of hospitalization considerably.
RCT Entities:
AIM: To assess whether the effectiveness of a combination of transarterial chemoembolization (TACE) and percutaneous ethanol injection (PEI) in the treatment of unresectable hepatocellular carcinoma (HCC) is superior to TACE alone a randomized controlled trial was performed. METHODS: The effect of combination therapy on long-term survival rates and duration of hospitalization was evaluated in 52 previously untreated HCCs, randomly allocated to TACE-PEI (27 pts) or TACE alone (25 pts). RESULTS: The cumulative survival rate of the TACE group was 75.8% at 6 mo, 62.9% at 12 mo, and 18.0% at 24 mo and of the TACE-PEI group 76.9%, 61.5%, and 38.7%, respectively. Comparison of overall survival in both groups showed no statistically significant difference. Regarding the patients with HCCs Okuda stage I (n = 26), the median survival of the TACE-PEI group was significantly longer (>24 mo, median not yet reached in the study period) compared to the TACE group (18.4 mo [range 11.6-21.7 mo]; P = 0.04). TACE-PEI reduced the relative risk for mortality to 0.4 (95%CI 0.15-0.96) compared to patients who received TACE alone. Median survival in patients with HCCs Okuda stage II or III was 5.0 mo in the TACE group (1.7 mo-not defined) compared to 10.4 mo in the TACE-PEI group. CONCLUSION: The combination TACE-PEI improved survival time compared to TACE alone. Our study revealed a statistically significant improved survival in HCCs Okuda stage I. Side effects were minor and the combination therapy did not prolong duration of hospitalization considerably.
Authors: J M Llovet; J Bustamante; A Castells; R Vilana; M del C Ayuso; M Sala; C Brú; J Rodés; J Bruix Journal: Hepatology Date: 1999-01 Impact factor: 17.425
Authors: K Yamamoto; M Masuzawa; M Kato; K Kurosawa; A Kaneko; H Ishida; E Imamura; N J Park; Y Shirai; K Fujimoto; T Michida; N Hayashi; M Ikeda Journal: Semin Oncol Date: 1997-04 Impact factor: 4.929
Authors: S Shiina; K Tagawa; T Unuma; H Fujino; Y Uta; Y Niwa; Y Hata; Y Komatsu; Y Shiratori; A Terano Journal: AJR Am J Roentgenol Date: 1990-12 Impact factor: 3.959
Authors: Angelo Andriulli; Ilario de Sio; Luigi Solmi; Luciano De Carlis; Roberto Troisi; Alessandro Grasso; Virginia Festa; Eugenio Caturelli; Alessandro Giacomoni; Camillo Del Vecchio Blanco; Bernard De Hemptinne; Andrew Burroughs; Francesco Perri Journal: Liver Transpl Date: 2004-11 Impact factor: 5.799
Authors: G F Stefanini; P Amorati; M Biselli; F Mucci; A Celi; V Arienti; R Roversi; C Rossi; G Re; G Gasbarrini Journal: Cancer Date: 1995-05-15 Impact factor: 6.860
Authors: L Mondazzi; R Bottelli; G Brambilla; A Rampoldi; I Rezakovic; C Zavaglia; A Alberti; G Idèo Journal: Hepatology Date: 1994-05 Impact factor: 17.425
Authors: Do Seon Song; Soon Woo Nam; Si Hyun Bae; Jin Dong Kim; Jeong Won Jang; Myeong Jun Song; Sung Won Lee; Hee Yeon Kim; Young Joon Lee; Ho Jong Chun; Young Kyoung You; Jong Young Choi; Seung Kew Yoon Journal: World J Gastroenterol Date: 2015-02-28 Impact factor: 5.742